|

Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection

RECRUITINGSponsored by University of Palermo
Actively Recruiting
SponsorUniversity of Palermo
Started2024-03-01
Est. completion2025-03-01
Eligibility
Age18 Years – 65 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06314113

Summary

The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.

Eligibility

Age: 18 Years – 65 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection

Exclusion Criteria:

* Pregnancy
* Concomitant pathologies causing immunosuppression
* Concurrent Immunomodulatory therapies
* Hormone replacement therapy
* High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma
* Previous history of L-SIL or higher grade lesions ≥ 24 months

Conditions2

CancerLow-Grade Intraepithelial Neoplasia of Cervix

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.